SENATE 607118th CongressRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

EFFECTIVE Act

Last Action: 3/1/2023

Actions

2023-03-01Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
2023-03-01Introduced in Senate

CRS Summary

As of 2023-03-01 (00)

Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act or the EFFECTIVE Act

This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug (i.e., opioid medication) upon a determination that the drug does not provide a significant advantage with respect to safety or effectiveness as compared to other drugs.

Cosponsors (2)

Mike Braun (R-IN)
Tammy Baldwin (D-WI)

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.